title: The beneficial effects of vitamin D3 on reducing antibody titers against Epstein-Barr virus in multiple sclerosis patients.
abstract: Recently, the relationship between immunoreactivity to Epstein-Barr virus (EBV) and hypo-vitamin D in multiple sclerosis (MS) patients has been described. The aim of this study was to investigate whether vitamin D3 supplementation in MS patients could influence the immune response against latent EBV infection. Forty MS patients were recruited in this study. Twenty-seven patients were supplemented with 50,000 IU/week of vitamin D3 for 6 months and thirteen enrolled as controls. 25-Hydroxyvitamin D (25OHD) levels and IgG titers against EBNA1 and VCA were determined pre- and post-supplementation. All the patients were seropositive for EBV prior to vitamin D supplementation. In this cohort, 22.5% and 47.5% of the MS patients had deficient and insufficient levels of 25OHD, respectively. Our findings confirm that antibody titers against EBV in MS patients rise after the onset of the disease and indicate that vitamin D3 supplementation could limit augmentation of these titers in MS patients.
authors: Department of Biology, Faculty of Sciences, University of Isfahan, Isfahan, Iran.
authors: Adeleh
authors: A
authors: Najafipoor
authors: Department of Biology, Faculty of Sciences, University of Isfahan, Isfahan, Iran. Electronic address: r.roghanian@sci.ui.ac.ir.
authors: Rasoul
authors: R
authors: Roghanian
authors: Department of Biology, Faculty of Sciences, University of Isfahan, Isfahan, Iran; Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
authors: Sayyed Hamid
authors: SH
authors: Zarkesh-Esfahani
authors: Department of Biology, Faculty of Sciences, University of Isfahan, Isfahan, Iran.
authors: Majid
authors: M
authors: Bouzari
authors: Department of Neurology, Al-Zahra Hospital, Isfahan University of Medical Sciences, Iran; Isfahan Research Committee of Multiple Sclerosis (IRCOMS), Isfahan, Iran.
authors: Masoud
authors: M
authors: Etemadifar
mesh_terms: D000328:Adult; D000914:Antibodies, Viral / Q000097:blood* / Q000276:immunology; D000956:Antigens, Viral / Q000276:immunology; D036022:Capsid Proteins / Q000276:immunology; D002762:Cholecalciferol / Q000008:administration & dosage*; D019587:Dietary Supplements; D020031:Epstein-Barr Virus Infections / Q000276:immunology; D019309:Epstein-Barr Virus Nuclear Antigens / Q000276:immunology; D005260:Female; D004854:Herpesvirus 4, Human / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D014807:Vitamin D / Q000031:analogs & derivatives* / Q000097:blood
chemical_list: D000914:Antibodies, Viral; D000956:Antigens, Viral; D036022:Capsid Proteins; D019309:Epstein-Barr Virus Nuclear Antigens; C041788:Epstein-Barr viral capsid antigen; D007074:Immunoglobulin G; D014807:Vitamin D; D002762:Cholecalciferol; C104450:25-hydroxyvitamin D; C417029:EBV-encoded nuclear antigen 1
keywords: 25-Hydroxyvitamin D (25OHD); Epstein–Barr nuclear antigen-1 (EBNA1); Epstein–Barr virus (EBV); Immune modulation; Multiple sclerosis (MS); Viral capsid antigen (VCA)